Dynamics of the PS1 and PS2 γ-Secretase Complexes
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
April 01, 2006 - March 31, 2008
Grant ID
A2006034
Acknowledgement
Summary
The long term objective of the proposed studies is to gain a better understanding of the function of y-secretase and to develop specific y-secretase inhibitors for treatment of Alzheimer’s disease (AD). y-Secretase cleaves the amyloid precursor protein (APP) to generate the C-termini of Aβ peptides (Aβ40 and Aβ42), in the final step of amyloid production. Aβ, the major constituent of amyloid plaques found in AD, is believed to play a critical role in the neuropathogenesis of AD. It is known that Aβ42 is more prone to aggregation than Aβ40 and increased Aβ42 production may accelerate the pathological cascade leading to AD. Mutations in PS1 and PS2 that lead to familial early-onset AD (FAD) cause an increased ratio of Aβ42/Aβ40. The precise mechanism by which these mutations result in the increased ratio of Aβ42/Aβ42 is unknown. The hypothesis that the dynamics of the PS1- and PS2-associated y-secretase complexes regulate the production of Aβ40 and Aβ42 and that deregulation of this process leads to production of excessive Aβ42. Dr. Li will investigate the complex dynamics through integrated approaches incorporating biochemistry, cell biology and chemical biology. The proposed studies will help to uncover the regulation and function of y-secretase, thereby facilitating the development of selective inhibitors for AD therapy.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD